Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615880 | 0.83 | ASIC3 (0.46) | MAPK14KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL24958732 | 0.76 | KDM4E (0.57) | MAPK14KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL12922238 | 0.75 | CCR1 (0.46) | TGFBR1MAPK14THRBKDM4EMEN1 | |
| SCHEMBL21610561 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2754041 | 0.73 | KDR (0.49) | — | |
| SCHEMBL8257857 | 0.72 | KDM4E (0.66) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL2609332 | 0.71 | KMT2A (0.60) | TGFBR1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL13615878 | 0.69 | ASIC3 (0.48) | TGFBR1CHRNA7 | |
| SCHEMBL25763705 | 0.69 | NPC1 (0.38) | TGFBR1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL786336 | 0.69 | PGK1 (0.39) | TGFBR1ALDH1A1MAPTHPGDCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | TGFBR1 3447/4885MAPK14 1977/4885THRB 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.